DrugPatentWatch Database Preview
Details for Patent: 7,439,393
Email this page to a colleague
Which drugs does patent 7,439,393 protect, and when does it expire?
Patent 7,439,393 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.
This patent has fifty-three patent family members in thirty countries.
Summary for Patent: 7,439,393
| Title: | Phenethanolamine derivatives for treatment of respiratory diseases |
| Abstract: | The invention relates to 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; and salts and solvates thereof, including those which are pharmaceutically acceptable, along with formulations thereof, combinations thereof, and methods for the treatment or prophylaxis of mammals by administering such compounds. |
| Inventor(s): | Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Mann; Inderjit Singh (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB) |
| Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
| Application Number: | 11/566,346 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Use; |
Drugs Protected by US Patent 7,439,393
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA. | ⤷ Try it Free | ||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA | ⤷ Try it Free | ||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER | ⤷ Try it Free | ||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,439,393
International Family Members for US Patent 7,439,393
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 036874 | ⤷ Try it Free | |||
| Argentina | 091595 | ⤷ Try it Free | |||
| Austria | 417606 | ⤷ Try it Free | |||
| Australia | 2002326026 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
